Malignant pleural mesothelioma

Baas, Paul; Schouwink, Hugo; Zoetmulder, F.A.N.

doi:10.1023/a:1008239116237

Cited by 69 publications

(38 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Doxorubicin, mitomycin, cisplatin, vinorelbine and high dose methotrexate are among the drugs showing some activity. Combination chemotherapy does not consistently appear to provide better results than single agents, although response rates have been higher in some studies (Ong and Vogelzang, 1996;Baas et al, 1998;Steele et al, 2000). The combination of cisplatin and gemcitabine was reported to be synergistic in terms of cytotoxicity, both in vitro and in vivo (Peters et al, 1995).…”

mentioning

confidence: 99%

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

Haarst¹,

Baas

Manegold³

et al. 2002

Br J Cancer

133

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efficacy and toxicity of a gemcitabine and cisplatin combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma. Method: Gemcitabine 1250 mg m 72 was administered on day 1 and day 8 and cisplatin 80 mg m 72 was administered on day 1 in a 3-week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were observed (ORR 16%, 95% CI 1 -31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred. Time to progression was 6 months (5 -7 months) with a median survival from registration of 9.6 months (95% CI 8 -12 months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule.

show abstract

mentioning

confidence: 99%

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

Haarst¹,

Baas

Manegold³

et al. 2002

Br J Cancer

133

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Approximately 3000 new cases are reported each year in the United States, and more than 10 000 are reported worldwide. 2,4 As mesothelioma symptoms do not arise until late stages, the majority of mesothelioma patients are diagnosed in an advanced stage of malignancy. 5 MM is resistant to all currently available treatments; therefore, understanding the mechanisms involved in the growth of MM may provide insights for the development of new therapeutic strategies to treat patients with MM.…”

Section: Introductionmentioning

confidence: 99%

EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene

et al. 2011

View full text Add to dashboard Cite

EphrinA1 binding with receptor EphA2 suppresses malignant mesothelioma (MM) growth. The mechanisms whereby EphrinA1 attenuates the MM cell (MMC) growth are not clear. In this study, we report that the activation of MMCs with EphrinA1 leads to an induction of let-7 microRNA (miRNA) expression, repression of RAS proto-oncogene and the attenuation of MM tumor growth. The expression of miRNAs was determined by reverse transcription-quantitative polymerase chain reaction and in situ hybridization. RAS expression was determined by q-PCR, western blotting and immunofluorescence. MMC proliferation and tumor growth were determined by WST-1 and Matrigel assay, respectively. EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. In contrast, EphrinA1 activation significantly downregulated H-RAS, K-RAS and N-RAS expression and inhibited MMC proliferation and tumor growth. In MMCs transfected with 2 0 -O-methyl antisense oligonucleotides to let-7 miRNA, EphrinA1 activation failed to inhibit the proliferative response and tumor growth. In mismatch antisense oligonucleotidetreated MMCs, the proliferation and tumor growth were comparable to untreated proliferating cells. Furthermore, the transfection of MMCs with let-7a miRNA precursor inhibited RAS expression and attenuated MMC tumor growth. Our data revealed that EphrinA1 signaling induces let-7 miRNA expression and attenuates MM tumor growth by targeting RAS proto-oncogene in MMCs.

show abstract

“…1,2 La primera descripción histológica de éste fue realizada por E. Wagner en 1870, y no fue sino hasta 1960 cuando J.C. Wagner y colaboradores establecieron una vinculación entre el mesotelioma maligno y la exposición a asbestos; así, describieron una enfermedad con un largo periodo de latencia, que afectaba fundamentalmente a mineros y trabajadores de molinos expuestos a crocidolita. [3][4][5] La incidencia del MM en el ámbito mundial es variable. En Estados Unidos de América (EUA) se han notificado 2 200 nuevos casos por año, con un incremento aproximado de 50% en la última década.…”

Section: Introductionunclassified

“…Se calcula que el riesgo de desarrollar enfermedad pleural secundaria a dicha exposición es de 8% -13%. 1,3,4 La radiación también parece tener un papel importante en el desarrollo del MM. 13 Así, en pacientes con diagnóstico de seminoma, cáncer de cérvix y linfoma de Hodgkin, tratados con radioterapia, se ha observado un aumento en la incidencia de MM.…”

Section: Introductionunclassified

“…[15][16][17] Histológicamente, el MM se divide en tres grupos: epitelial, sarcomatoide y mixto. 1,3,4 El tipo sarcomatoide se asocia con grandes masas tumorales, ausencia o mínimo derrame pleural y mayor frecuencia de metástasis hematógenas. El tipo epitelial constituye aproximadamente 60% del total, y se subdivide en tubulopapilar, glandular y sólido.…”

Section: Introductionunclassified

See 1 more Smart Citation

Mesotelioma maligno: descripción clínica y radiológica de 45 casos con y sin exposición a asbestos

García-López

Rodríguez

2000

Salud pública Méx

View full text Add to dashboard Cite

Malignant pleural mesothelioma

Cited by 69 publications

References 90 publications

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene

Mesotelioma maligno: descripción clínica y radiológica de 45 casos con y sin exposición a asbestos

Contact Info

Product

Resources

About